SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Feb 20, 15:47
2903.75
-11.55 (-0.4%)
VOLUME 20,686
LIVE
NSE
Feb 20, 15:59
2898.75
-13.95 (-0.48%)
VOLUME 560,362
News on Dr Reddys Laboratories
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Sell Havells, Dr Reddy's; buy Petronet, Siemens: Sukhani 

10.19 am | 20 Feb 2017 |  Source: CNBC-TV18

Sudarshan Sukhani of s2analytics.com is of the view that one can sell Havells India and Dr Reddy's Labs and advises buying Petronet LNG and Siemens....

Buy, sell, hold: 7 stocks analysts are watching out

9.48 am | 20 Feb 2017 |  Source: Moneycontrol.com

Goldman Sachs says Kotak Mahindra Bank may outperform on improving growth prospects & top quartile EPS growth. Lending book is likely to grow at 25 pe...

Six in Sixty: Stocks you should keep on your radar 

2.56 pm | 16 Feb 2017 |  Source: CNBC-TV18

CNBC-TV18's Ekta Batra lists six stocks that you should focus on – Infosys, Tata Consultancy Services (TCS), Dr Reddys Laboratories, Sun Pharmaceuti...

Top buzzing midcap stocks to trade on February 16 

1.30 pm | 16 Feb 2017 |  Source: CNBC-TV18

Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today – Dr Reddys, TCS, Fortis Health, SBI and IL&FS Engineering....

Buy Dr Reddy’s Laboratories 2850 Put: Mitessh Thakkar 

11.52 am | 16 Feb 2017 |  Source: CNBC-TV18

Mitessh Thakkar of miteshthacker.com is of the view that one can buy Dr Reddy’s Laboratories 2850 Put while he feels that the trend in Tata Motors D...

DRL gets adverse ruling in US over patent infringement case

11.14 am | 16 Feb 2017 |  Source: PTI

In a BSE filing, Reddy's Laboratories said: "The United States District Court for the District of New Jersey issued its opinion regarding Helsinn Heal...

Dr Reddy's gets unfavourable ruling in US over anti-nausea drug 

10.31 am | 16 Feb 2017 |  Source: Moneycontrol.com

Dr Reddy's on Thursday said it received an unfavorable ruling in a US court regarding a patent infringement case over its anti-nausea injection Aloxi....

Dr Reddy's Lab announces US district court's opinion relating to patent infringement

10.03 am | 16 Feb 2017 |  Source: Moneycontrol.com

Dr Reddys announced that the United States District Court for the district of New Jersey issued it opinion regarding Helsinn Healthcares patent infr...

FIIs' stake in Nifty cos at 6-quarter low in Q3; Infosys dumped

3.18 pm | 15 Feb 2017 |  Source: Moneycontrol.com

Foreign institutional investors (FIIs) pared their equity holdings in frontline Indian companies during the December quarter, with market watchers bla...

Dr Reddy's, Aurobindo recall drugs from US market

2.40 pm | 15 Feb 2017 |  Source: PTI

According to a notification issued by the US Food and Drug Authority, Dr Reddy's is recalling Olanzapine tablets USP of 2.5 mg while Aurobindo is reca...

Cipla joins the race to build specialty branded business in US

4.56 pm | 13 Feb 2017 |  Source: Moneycontrol.com

Cipla will be falling back on its core strengths in respiratory and central nervous system (CNS) for build-up of specialty pipeline in US. The company...

See at least two US Fed rate hikes this year: Sanjeev Prasad 

11.05 am | 13 Feb 2017 |  Source: CNBC-TV18

The strength of the US dollar will decide the fate of the emerging markets (EMs), said Sanjeev Prasad, Senior ED & Co-Head at Kotak Institutional Equi...

Dr Reddy's launches generic drugs in France; expands Ops in

2.42 pm | 10 Feb 2017 |  Source: PTI

According to a recently issued statement, the products will be made available in the hospital market in March this year in the area of oncology and an...

Hold Dr Reddy's Lab; target of Rs 2970: Centrum

2.38 pm | 10 Feb 2017 |  Source: Moneycontrol.com

Centrum recommended hold rating on Dr Reddy's Lab with a target price of Rs 2970 in its research report dated February 06, 2017....

Aurobindo forays into biosimilars with Swiss acquisition

10.30 pm | 09 Feb 2017 |  Source: Moneycontrol.com

Aurobindo Pharma forayed into biosimilars with acquisition of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutica...

Hold Dr Reddy’s Laboratories; target of Rs 2930: ICICI Direct

5.28 pm | 09 Feb 2017 |  Source: Moneycontrol.com

ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 2930 in its research report dated February 07, 2017....

Accumulate Dr. Reddy’s Lab; target of Rs 3523: KR Choksey

3.36 pm | 09 Feb 2017 |  Source: Moneycontrol.com

KR Choksey has recommended accumulate rating on Dr. Reddy’s Laboratories with a target price of Rs 3523 in its research report dated February 06, 20...

Dr Reddy's US launch of cancer drug delayed over compliance woes

6.00 pm | 08 Feb 2017 |  Source: Moneycontrol.com

The drug maker’s much anticipated launch of key blood cancer treatment drug imatinib mesylate in US – is facing the risk of further delay, as a pa...

Hold Dr. Reddys Laboratories; target of Rs 3175: Edelweiss

5.39 pm | 08 Feb 2017 |  Source: Moneycontrol.com

Edelweiss is bullish on Dr. Reddys Laboratories has recommended hold rating on the stock with a target price of Rs 3175 in its research report dated F...

Govt needs to be a strong enabler in pharma sector: Experts 

10.14 pm | 07 Feb 2017 |  Source: CNBC-TV18

Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward fo...

1 2 3
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.